JOHNSON + JOHNSON DL 1
stock DE:JNJ (FRANKFURT)

Alternative ID: US4781601046

Watch List

Exchange: FRANKFURT
Sector: Healthcare
Industry: Drug Manufacturers—General
Market Cap: Mega (441.7B)
Data in EUR

EPS: 4.71
Current PE: 32.37
BVPS: 23.73
Price/BVPS: 6.49
Dividend: 4.04 / 2.4%

Hist Grade: D (45.40)
YOY Grade: E (30.62)
Debt/FCF: 1.43
ROIC: 17.8%
PEG: 2.43
PEGY: 2.06

Value Price: 42.54
MOS Price: 21.27
MOS %: -72.4%
Graham Number: 50.13
Graham MOS %: -67.4%
IRT: 18.32

Market Price

153.89

0.00 0.0%

as of Mar 21 '23

52 Week Range:

150.71 180.93

Stock Analyzer Tutorials

General Info

type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

Financial Statements

type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

Growth Grade and Financial Ratios

type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

Price Charts

type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Exchange: FRANKFURT
Sector: Healthcare
Industry: Drug Manufacturers—General
Market Cap: Mega (441.7B)
Inst. Ownership: 70.62%
Insider Ownership: 0.10%
Full Time Employees: 141700

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement

Cash Flow Statement

Balance Sheet

Liquidity Ratios

Current Ratio

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name	Dec '14	Dec '15	Jan '16	Dec '16	Jan '17	Oct '17	Dec '18	Dec '19	Jan '21	Oct '21	Jan '22
Equity (BVPS)	22.64	23.67		25.30		23.10	21.23	19.78	19.99	23.50
growth rate		4.6%		3.4%		-4.5%	-8.1%	-6.8%	1.1%	17.6%
Earnings BIT	21,137.00		18,370.00		21,165.00	18,897.00	21,175.00	21,263.00	20,314.00		25,247.00
growth rate			-6.8%		7.3%	-10.7%	12.1%	0.4%	-4.5%		11.5%
Avg.PE	16.08	17.63		19.71		226.23	20.94	23.96	24.27	24.97	24.97
growth rate		9.6%		5.7%		238.8%	-90.7%	14.4%	1.3%	2.9%	0.0%
ROA	12.38	11.65		12.05		0.87	9.86	9.73	8.85	11.70
growth rate		-5.9%		1.7%		-73.1%	1,033.3%	-1.3%	-9.0%	32.2%
ROE	22.70	21.87		23.37		1.99	25.51	25.36	23.97	30.41
growth rate		-3.7%		3.4%		-70.8%	1,181.9%	-0.6%	-5.5%	26.9%
ROIC	18.47	17.55		17.86		1.69	16.90	17.01	15.93	20.35
growth rate		-5.0%		0.9%		-69.2%	900.0%	0.7%	-6.4%	27.8%
Cur. Ratio	2.36	2.17		2.47		1.41	1.47	1.26	1.21	1.35
growth rate		-8.1%		6.7%		-24.5%	4.3%	-14.3%	-4.0%	11.6%
Quick Ratio	1.75	1.77		2.04		1.04	1.08	0.94	0.91	1.04
growth rate		1.1%		7.4%		-28.6%	3.9%	-13.0%	-3.2%	14.3%
Leverage	1.88	1.88		2.01		2.61	2.56	2.65	2.76	2.46
growth rate		0.0%		3.4%		14.0%	-1.9%	3.5%	4.2%	-10.9%
Balance Sheet	Dec '14	Dec '15	Jan '16	Dec '16	Jan '17	Oct '17	Dec '18	Dec '19	Jan '21	Oct '21	Jan '22
Acct.Receivable	10,985.00		10,734.00		11,699.00	13,490.00	14,098.00	14,481.00	13,576.00		15,283.00
growth rate			-1.2%		4.4%	15.3%	4.5%	2.7%	-6.3%		6.1%
Acct.Payable	7,633.00		6,668.00		6,918.00	7,310.00	7,537.00	8,544.00	9,505.00		11,055.00
growth rate			-6.5%		1.9%	5.7%	3.1%	13.4%	11.3%		7.9%
Cur.Assets	55,744.00		60,210.00		65,032.00	43,088.00	46,033.00	45,274.00	51,237.00		60,979.00
growth rate			3.9%		3.9%	-33.7%	6.8%	-1.7%	13.2%		9.1%
Total Assets	130,358.00		133,411.00		141,208.00	157,303.00	152,954.00	157,728.00	174,894.00		182,018.00
growth rate			1.2%		2.9%	11.4%	-2.8%	3.1%	10.9%		2.0%
Cash	14,523.00		13,732.00		18,972.00	17,824.00	18,107.00	17,305.00	13,985.00		14,487.00
growth rate			-2.8%		17.5%	-6.1%	1.6%	-4.4%	-19.2%		1.8%
Inventory	8,184.00		8,053.00		8,144.00	8,765.00	8,599.00	9,020.00	9,344.00		10,387.00
growth rate			-0.8%		0.6%	7.6%	-1.9%	4.9%	3.6%		5.4%
Cur.Liabilities	25,031.00		27,747.00		26,287.00	30,537.00	31,230.00	35,964.00	42,493.00		45,226.00
growth rate			5.3%		-2.7%	16.2%	2.3%	15.2%	18.2%		3.2%
Liabilities	60,606.00		62,261.00		70,790.00	97,143.00	93,202.00	98,257.00	111,616.00		107,995.00
growth rate			1.4%		6.6%	37.2%	-4.1%	5.4%	13.6%		-1.6%
LT Debt	15,130.00		13,096.00		22,824.00	30,684.00	27,687.00	26,494.00	32,635.00		29,985.00
growth rate			-7.0%		32.0%	34.4%	-9.8%	-4.3%	23.2%		-4.2%
Equity	69,752.00		71,150.00		70,418.00	60,160.00	59,752.00	59,471.00	63,278.00		74,023.00
growth rate			1.0%		-0.5%	-14.6%	-0.7%	-0.5%	6.4%		8.2%
Common Shares	2,864.00	2,813.00		2,789.00		2,745.00	3,120.00	3,120.00	3,120.00	3,120.00
growth rate		-1.8%		-0.4%		-0.8%	13.7%	0.0%	0.0%	0.0%
Cash Flow Statement	Dec '14	Dec '15	Jan '16	Dec '16	Jan '17	Oct '17	Dec '18	Dec '19	Jan '21	Oct '21	Jan '22
Capital Expenditures	3,714.00		3,463.00		3,226.00	3,279.00	3,670.00	3,498.00	3,347.00		3,652.00
growth rate			-3.4%		-3.5%	1.6%	11.9%	-4.7%	-4.3%		4.5%
Cash Dividends	7,768.00		8,173.00		8,621.00	8,943.00	9,494.00	9,917.00	10,481.00		11,032.00
growth rate			2.6%		2.7%	3.7%	6.2%	4.5%	5.7%		2.6%
Cash From OA	18,710.00		19,569.00		18,767.00	21,056.00	22,201.00	23,416.00	23,536.00		23,410.00
growth rate			2.3%		-2.1%	12.2%	5.4%	5.5%	0.5%		-0.3%
FCF per Share	4.18	4.85		4.53		5.62	5.91	6.53	5.59	7.40
growth rate		16.0%		-3.4%		11.4%	5.2%	10.5%	-14.4%	32.4%
Sale Purchase of Stock	1,543.00		1,005.00		1,189.00	1,062.00
growth rate			-19.3%		8.8%	-10.7%
FCF	14,757.00	15,816.00	16,106.00	15,541.00	15,541.00	17,777.00	18,531.00	19,918.00	20,189.00	19,758.00	19,758.00
growth rate		7.2%	1.8%	-3.5%	0.0%	14.4%	4.2%	7.5%	1.4%	-2.1%	0.0%
Income Statement	Dec '14	Dec '15	Jan '16	Dec '16	Jan '17	Oct '17	Dec '18	Dec '19	Jan '21	Oct '21	Jan '22
Sales	74,331.00		70,074.00		71,890.00	76,450.00	81,581.00	82,059.00	82,584.00		93,775.00
growth rate			-2.9%		1.3%	6.3%	6.7%	0.6%	0.6%		6.6%
Op.Income	21,137.00		18,370.00		21,165.00	18,897.00	21,175.00	21,263.00	20,314.00		25,247.00
growth rate			-6.8%		7.3%	-10.7%	12.1%	0.4%	-4.5%		11.5%
IBT	20,563.00		19,196.00		19,803.00	17,673.00	17,999.00	17,328.00	16,497.00		22,776.00
growth rate			-3.4%		1.6%	-10.8%	1.8%	-3.7%	-4.8%		17.5%
Net Income	16,323.00		15,409.00		16,540.00	1,300.00	15,297.00	15,119.00	14,714.00		20,878.00
growth rate			-2.8%		3.6%	-92.1%	1,076.7%	-1.2%	-2.7%		19.1%
EPS	5.70	5.48		5.93		0.47	5.61	5.63	5.51	7.81
growth rate		-3.9%		4.0%		-71.9%	1,093.6%	0.4%	-2.1%	41.7%
Gross Profit	51,585.00		48,619.00		50,101.00	51,011.00	54,490.00	54,503.00	54,157.00		64,020.00
growth rate			-2.9%		1.5%	1.8%	6.8%	0.0%	-0.6%		8.7%
R&D	8,494.00		9,046.00		9,143.00	10,594.00	10,775.00	11,355.00	12,159.00		14,714.00
growth rate			3.2%		0.5%	15.9%	1.7%	5.4%	7.1%		10.0%

Quarterly Statements

Item Name	Oct '21	Jan '22	Apr '22	Jul '22	Oct '22
Earnings BIT	6,836.00	5,155.00	6,743.00	6,478.00	6,298.00
growth rate		-24.6%	30.8%	-3.9%	-2.8%
Balance Sheet	Oct '21	Jan '22	Apr '22	Jul '22	Oct '22
Acct.Receivable	14,911.00	15,283.00	15,594.00	16,139.00
growth rate		2.5%	2.0%	3.5%
Acct.Payable	8,961.00	11,055.00	9,309.00	9,765.00
growth rate		23.4%	-15.8%	4.9%
Cur.Assets	59,889.00	60,979.00	60,424.00	63,847.00
growth rate		1.8%	-0.9%	5.7%
Total Assets	179,228.00	182,018.00	178,355.00	177,724.00
growth rate		1.6%	-2.0%	-0.4%
Cash	17,604.00	14,487.00	10,463.00	10,983.00
growth rate		-17.7%	-27.8%	5.0%
Inventory	10,387.00	10,387.00	10,990.00	11,437.00
growth rate		0.0%	5.8%	4.1%
Cur.Liabilities	44,561.00	45,226.00	43,390.00	44,821.00
growth rate		1.5%	-4.1%	3.3%
Liabilities	108,956.00	107,995.00	103,646.00	101,367.00
growth rate		-0.9%	-4.0%	-2.2%
LT Debt	30,130.00	29,985.00	28,851.00	28,292.00
growth rate		-0.5%	-3.8%	-1.9%
Equity	70,272.00	74,023.00	74,709.00	76,357.00	76,357.00
growth rate		5.3%	0.9%	2.2%	0.0%
Common Shares	3,120.00	3,120.00	3,120.00	3,120.00
growth rate		0.0%	0.0%	0.0%
Cash Flow Statement	Oct '21	Jan '22	Apr '22	Jul '22	Oct '22
Capital Expenditures	747.00	1,415.00	607.00	863.00
growth rate		89.4%	-57.1%	42.2%
Cash Dividends	2,791.00	2,791.00	2,787.00	2,971.00
growth rate		0.0%	-0.1%	6.6%
Cash From OA	8,290.00	5,732.00	3,979.00	5,581.00
growth rate		-30.9%	-30.6%	40.3%
Sale Purchase of Stock
growth rate
FCF	7,543.00	4,317.00	3,372.00	4,718.00
growth rate		-42.8%	-21.9%	39.9%
Income Statement	Oct '21	Jan '22	Apr '22	Jul '22	Oct '22
Sales	23,338.00	24,804.00	23,426.00	24,020.00	23,791.00
growth rate		6.3%	-5.6%	2.5%	-1.0%
Op.Income	6,836.00	5,155.00	6,743.00	6,478.00	6,298.00
growth rate		-24.6%	30.8%	-3.9%	-2.8%
IBT	3,849.00	4,836.00	5,862.00	5,840.00	5,822.00
growth rate		25.6%	21.2%	-0.4%	-0.3%
Net Income	3,667.00	4,736.00	5,149.00	4,814.00	4,458.00
growth rate		29.2%	8.7%	-6.5%	-7.4%
EPS
growth rate
Gross Profit	16,106.00	16,884.00	15,844.00	16,118.00	15,984.00
growth rate		4.8%	-6.2%	1.7%	-0.8%
R&D	3,422.00	4,720.00	3,462.00	3,703.00	3,597.00
growth rate		37.9%	-26.7%	7.0%	-2.9%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

D (45.40)

YOY Growth Grade:

E (30.62)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Dividend Yield: 2.4%
Beta: 0.56
Beta of 0.5590 suggests that the asset is less volatile than the rest of the market.
PE: 32.37
EY: 3.1%
PEG: 2.43
PEG Ratio of 2.43 suggests that stock is overpriced.
PEGY: 2.06
PEGY Ratio of 2.06 suggests that stock is overpriced.
Price/BVPS: 6.49

Profitability Ratios

ROE: 30.4%
Return on Equity (ROE) of 30.4% suggests that a company is doing well.
ROS: 26.9%
The value of Return on Sales depends on the business and/or industry. Usually the higher ratio the better.
ROA: 12.5%
Return on Assets (ROA). Low ratio usually means poor performance, or ineffective use of assets by management. High ratio usually means good performance.
ROI: 30.8%
Return on Investment (ROI) of 30.8% suggests that a company is doing well.
ROIC: 17.8%
Return on Invested Capital (ROIC) of 17.8% suggests that a company is doing well.

Liquidity Ratios

Current Ratio: 1.35
Current Ratio of 1.35 suggests that a company may not be able to pay off bills as rapidly as it should.
Quick Ratio: 0.66
Quick Ratio of 0.66 suggests that a company does not have enough cash to cover immediate liabilities.
Cash Turnover: 5.95
Turnover Of Cash Ratio of 5.95 suggests that a company may be vulnerable to creditors. As a result it may be unable to pay wages or utility bills.
Equity Ratio: 40.7%
Equity Ratio of 40.7% suggests that a company has high financing and debt service costs, not very attractive to investors.
Debt/Equity: 145.9%
Debt to Equity Ratio of 145.9% suggests that greater risk assumed by creditors, hence greater interest by them in the way the company is being managed.
Debt/FCF: 1.43
Debt/FCF of 1.43 suggests that a company is doing well and can pay off its long term debt within three years.

Efficiency Ratios

Avg Collection Period: 59.49
Average Collection Period of 59.49 days suggests that a company is doing well.
Inventory Turnover: 2.86
Inventory Turnover Ratio of 2.86 suggests a large inventory, a never-out-of-stock situation, perhaps some obsolete items, or it could indicate poor liquidity and possible overstocking of items.
Cash Flow Ratio: 2.32
Cash Flow Ratio of 2.32 suggests a company is doing OK, but lower inventory is generally viewed as a positive trend.
Profit Margin: 22.3%

Value Price

PE and EPS

	Historical	Current	Forward
PE	35.64	32.69	16.69
EPS / Growth		4.71

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 5.6%

Estimates	Pessimistic	Moderate	Optimistic
Rate of Return	15.0%
MOS Price %	50 %
Future EPS Growth	5.6%	5.6%	5.6%
Future PE	11.22	21.18	21.18
Future EPS	8.12	8.12	8.12
Value Price MOS %	22.53 -85.4%	42.54 -72.4%	42.54 -72.4%
MOS Price	11.27	21.27	21.27
IRT	18.44	18.44	18.44

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Graham Number: 50.13
Graham MOS: -67.4%

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.